RecruitingNCT07523633
Semaglutide and cannabis use in adults
About this title
Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder
Read the official source — NCT07523633Medication studyAges 18–70DenmarkAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 70 years.
- Listed locations
- FrederiksbergSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 30, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 100
- Sponsor
- Anders Fink-Jensen, MD, DMSci
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Denmark
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT07523633
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Trial of Semaglutide for Reducing Cannabis Use in Adults With Cannabis Use Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Frederiksberg
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Anders Fink-Jensen, MD, DMSci.
Does this study involve medication?
Yes. The study involves medication, including semaglutide and Placebo.
Who can participate?
Listed age limits: 18 years to 70 years.
Is this study still recruiting?
The registry lists this study as recruiting.
